TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Maze Therapeutics (NASDAQ: MAZE)The analyst comments "MAZE829's 62% uACR ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE